Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: resembling (46)

Carboplatin (AUC5) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat (AUC5) Regimen • Ovary – Carboplatin (AUC5) Retreat Indication • Second line or subsequent treatment of platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-Retreat.pdf

Carboplatin (AUC4)-Gemcitabine (day 1, 8) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Retreat Regimen • Ovary-Carboplatin (AUC4)-Gemcitabine (1, 8) Retreat Indication • Recurrent
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabineday18Retreat.pdf

Bevacizumab (15) Carboplatin-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Cervix-Bevacizumab (15)-Carboplatin (AUC5)-Paclitaxel (21 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/Bevacizumab-15-Carboplatin-Paclitaxel-21-day.pdf

Carboplatin(AUC5)-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Cervix-Carboplatin (AUC5)-Paclitaxel (21 day) Indication • Neoadjuvant treatment of cervical
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CarboplatinAUC5-Paclitaxel-21day.pdf

CarboplatinAUC5 Etoposide IV/PO

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-ETOPOSIDE (Intravenous / Oral) Regimen • Ovary – Carboplatin (AUC5)-Etoposide IV/PO Indication • Small cell or neuroendocrine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-EtoposideIVPO.pdf

CarboplatinAUC4-Gemcitabine (day 1,8)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Regimen  Ovary-Carboplatin (AUC4)-Gemcitabine (1, 8) Indication  Recurrent platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabine-day18.pdf

SoAR RLP Deputy Lead Role JD and PS

Description: Southampton Academy of Research (SoAR) Research Leaders Programme (RLP) Deputy Lead: Call for expressions of interest University of Southampton NHS Foundation
Url: /Media/Southampton-Clinical-Research/Downloads/SoAR-RLP-Deputy-Lead-Role-JD-and-PS.pdf

Zanubrutinib Ver1

Description: Chemotherapy Protocol LYMPHOMA ZANUBRUTINIB Regimen • Lymphoma - Zanubrutinib Indication Zanubrutinib monotherapy for the treatment of patients with previously treated Waldenstrom’s macroglobulinaemia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Zanubrutinib.pdf

Asciminib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Asciminib Regimen • Asciminib Indication • Patients with chronic phase Philadelphia chromosome-positive chronic myeloid Leukaemia previously treated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Asciminib.pdf

CarboplatinAUC4-Gemcitabine (1)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC4)-GEMCITABINE (day 1) Regimen • Ovary-Carboplatin (AUC4)-Gemcitabine (1) Indication • Recurrent platinum sensitive ovarian cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC4-Gemcitabine1.pdf

391 to 400 of 757

Previous … 38 39 40 41 42 … Next